Clinical Trial Update: Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of Dolastatin 10 in patients with indolent non-Hodgkin lymphoma, Waldenström's macroglobulinemia, or chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Dolastatin 10 (dolastatin-10)

Snippet

Sponsor: University of Vermont | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED